Next Article in Journal
Donor–Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation
Previous Article in Journal
Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives
Article

Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study

1
Adelphi Real World, Bollington SK10 5JB, UK
2
Pfizer Inc., New York, NY 10017, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(1), 678-688; https://doi.org/10.3390/curroncol28010066
Received: 20 August 2020 / Revised: 17 December 2020 / Accepted: 12 January 2021 / Published: 24 January 2021
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study (NCT03159195) collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. View Full-Text
Keywords: palbociclib; Canada; metastatic breast cancer; real-world; retrospective; medical chart review palbociclib; Canada; metastatic breast cancer; real-world; retrospective; medical chart review
Show Figures

Figure 1

MDPI and ACS Style

Mycock, K.; Zhan, L.; Taylor-Stokes, G.; Milligan, G.; Mitra, D. Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study. Curr. Oncol. 2021, 28, 678-688. https://doi.org/10.3390/curroncol28010066

AMA Style

Mycock K, Zhan L, Taylor-Stokes G, Milligan G, Mitra D. Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study. Current Oncology. 2021; 28(1):678-688. https://doi.org/10.3390/curroncol28010066

Chicago/Turabian Style

Mycock, Katie; Zhan, Lin; Taylor-Stokes, Gavin; Milligan, Gary; Mitra, Debanjali. 2021. "Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study" Curr. Oncol. 28, no. 1: 678-688. https://doi.org/10.3390/curroncol28010066

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop